KMT5B

Across TCGA pan-cancer cohorts, KMT5B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KMT5B data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KMT5B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated KMT5B expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where KMT5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.937	0.686	.003	37	view →
PDAC	OS	Median	II,III,IV	0.300	0.727	.007	29	view →
UCEC	DFS	Median	III,IV	1.000	0.483	.014	12	view →
LUAD	OS	Median	All	0.926	1.000	.022	8	view →
GBM	OS	Quartile	All	0.624	0.340	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KMT5B–LSCC (OS)

Open the LSCC breakdown →